PP2A: The Wolf in Sheep's Clothing?

被引:62
作者
Kiely, Maeve [1 ,2 ]
Kiely, Patrick A. [1 ,2 ,3 ]
机构
[1] Univ Limerick, Dept Life Sci, Limerick 78666, Ireland
[2] Univ Limerick, Mat & Surface Sci Inst, Limerick 78666, Ireland
[3] Univ Limerick, Stokes Inst, Limerick, Ireland
基金
爱尔兰科学基金会;
关键词
phosphatase; PP2A; cellular signaling; tumour suppressor; cancer; PROTEIN PHOSPHATASE 2A; ACUTE MYELOID-LEUKEMIA; MAP KINASE PATHWAY; A-ALPHA SUBUNIT; SMALL-T-ANTIGEN; CELLS IN-VITRO; REGULATORY SUBUNIT; CANCER CELLS; OKADAIC ACID; ORAL FINGOLIMOD;
D O I
10.3390/cancers7020648
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Protein Phosphatase 2A (PP2A) is a major serine/threonine phosphatase in cells. It consists of a catalytic subunit (C), a structural subunit (A), and a regulatory/variable B-type subunit. PP2A has a critical role to play in homeostasis where its predominant function is as a phosphatase that regulates the major cell signaling pathways in cells. Changes in the assembly, activity and substrate specificity of the PP2A holoenzyme have a direct role in disease and are a major contributor to the maintenance of the transformed phenotype in cancer. We have learned a lot about how PP2A functions from specific mutations that disrupt the core assembly of PP2A and from viral proteins that target PP2A and inhibit its effect as a phosphatase. This prompted various studies revealing that restoration of PP2A activity benefits some cancer patients. However, our understanding of the mechanism of action of this is limited because of the complex nature of PP2A holoenzyme assembly and because it acts through a wide variety of signaling pathways. Information on PP2A is also conflicting as there are situations whereby inactivation of PP2A induces apoptosis in many cancer cells. In this review we discuss this relationship and we also address many of the pertinent and topical questions that relate to novel therapeutic strategies aimed at altering PP2A activity.
引用
收藏
页码:648 / 669
页数:22
相关论文
共 145 条
[71]   Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS [J].
List, A. F. ;
Bennett, J. M. ;
Sekeres, M. A. ;
Skikne, B. ;
Fu, T. ;
Shammo, J. M. ;
Nimer, S. D. ;
Knight, R. D. ;
Giagounidis, A. .
LEUKEMIA, 2014, 28 (05) :1033-1040
[72]   Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL [J].
Liu, Li ;
Greger, James ;
Shi, Hong ;
Liu, Yuan ;
Greshock, Joel ;
Annan, Roland ;
Halsey, Wendy ;
Sathe, Ganesh M. ;
Martin, Anne-Marie ;
Gilmer, Tona M. .
CANCER RESEARCH, 2009, 69 (17) :6871-6878
[73]   Norcantharidin induces melanoma cell apoptosis through activation of TR3 dependent pathway [J].
Liu, Shujing ;
Yu, Hong ;
Kumar, Suresh M. ;
Martin, James S. ;
Bing, Zhanyong ;
Sheng, Weiqi ;
Bosenberg, Marcus ;
Xu, Xiaowei .
CANCER BIOLOGY & THERAPY, 2011, 12 (11) :1005-1014
[74]   The effect of a PP2A inhibitor on the nuclear receptor corepressor pathway in glioma Laboratory investigation [J].
Lu, Jie ;
Zhuang, Zhengping ;
Song, Debbie K. ;
Mehta, Gautam U. ;
Ikejiri, Barbara ;
Mushlin, Harry ;
Park, Deric M. ;
Lonser, Russell R. .
JOURNAL OF NEUROSURGERY, 2010, 113 (02) :225-233
[75]   Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms [J].
Lu, Jie ;
Kovach, John S. ;
Johnson, Francis ;
Chiang, Jeffrey ;
Hodes, Richard ;
Lonser, Russell ;
Zhuang, Zhengping .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (28) :11697-11702
[76]   Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance [J].
MacKeigan, JP ;
Murphy, LO ;
Blenis, J .
NATURE CELL BIOLOGY, 2005, 7 (06) :591-U19
[77]  
Marc M., 2007, CELL, V130, P21, DOI 10.1016/j.cell.2007.06.03417632053
[78]  
Marvaso G, 2014, CANCER BIOL THER, V15, P1
[79]   A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells [J].
Matsuoka, Y ;
Nagahara, Y ;
Ikekita, M ;
Shinomiya, T .
BRITISH JOURNAL OF PHARMACOLOGY, 2003, 138 (07) :1303-1312
[80]   Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas [J].
McConechy, Melissa K. ;
Anglesio, Michael S. ;
Kalloger, Steve E. ;
Yang, Winnie ;
Senz, Janine ;
Chow, Christine ;
Heravi-Moussavi, Alireza ;
Morin, Gregg B. ;
Mes-Masson, Anne-Marie ;
Carey, Mark S. ;
McAlpine, Jessica N. ;
Kwon, Janice S. ;
Prentice, Leah M. ;
Boyd, Niki ;
Shah, Sohrab P. ;
Gilks, C. Blake ;
Huntsman, David G. .
JOURNAL OF PATHOLOGY, 2011, 223 (05) :567-573